

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5627383

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ADEL MOUSSA	07/19/2019
JEAN-PIERRE SOMMADOSSI	07/19/2019
RECEIVING PARTY DATA	
Name:	ATEA PHARMACEUTICALS, INC.
Street Address:	125 SUMMER STREET
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02110
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	15885630
PCT Number:	US2018016301
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6786941262
Email:	docket@kipsllc.com
Correspondent Name:	KNOWLES INTELLECTUAL PROPERTY STRATEGIES, LLC
Address Line 1:	400 PERIMETER CENTER TERRACE NE,
Address Line 2:	SUITE 200
Address Line 4:	ATLANTA, GEORGIA 30346
ATTORNEY DOCKET NUMBER:	12020-009US1 AND 009WO1
NAME OF SUBMITTER:	BRENT R. BELLOWS
SIGNATURE:	/Brent R. Bellows/
DATE SIGNED:	07/19/2019
Total Attachments: 4	
source=12020-009WO1_2019-07-19_executedAssignment#page1.tif	
source=12020-009WO1_2019-07-19_executedAssignment#page2.tif	
source=12020-009WO1_2019-07-19_executedAssignment#page3.tif	

ASSIGNMENT

WHEREAS, we **ADEL MOUSSA** of Burlington, Massachusetts; and **JEAN-PIERRE SOMMADOSSI** of Boston, Massachusetts (“Assignors”), have invented certain new and useful inventions disclosed in the International Patent Application titled **“NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS,”** filed in the United States Patent and Trademark Office acting as the Receiving Office on **January 31, 2018** and assigned PCT Application No. **PCT/US2018/016301**; U.S. Non-provisional Patent Application titled **“Nucleotide Hemi-Sulfate Salt For The Treatment of Hepatitis C Virus,”** filed in the United States Patent and Trademark Office on January 31, 2018, and assigned U.S. Application No. 15/885,630; Taiwan Patent Application titled **“NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS,”** filed in the Taiwan Intellectual Property Patent Office on **February 1, 2018** and assigned ROC (Taiwan) Patent Application No. **107103671**; and Argentina Patent Application titled **“NUCLEOTIDE HEMI-SULFATE SALT FOR THE TREATMENT OF HEPATITIS C VIRUS,”** filed in the National Institute of Industrial Property Office in Argentina on **February 1, 2018** and assigned Argentine Patent Application No. **20180100244** (hereinafter referred to collectively as the **“Applications”**). The Applications claim priority to U.S. Provisional Application No. 62/453,437, filed in the U.S. Patent and Trademark Office on February 1, 2017; U.S. Provisional Application No. 62/469,912, filed in the U.S. Patent and Trademark Office on March 10, 2017; U.S. Provisional Application No. 62/488,366, filed in the U.S. Patent and Trademark Office on April 21, 2017; and U.S. Provisional Application No. 62/575,248, filed in the U.S. Patent and Trademark Office on October 20, 2017, and for which applications for Letters Patent in the United States, Taiwan, Argentina, and other foreign jurisdictions have been or will be made; and

WHEREAS, **ATEA PHARMACEUTICALS, INC.** (“Assignee”), a business entity organized and existing under the laws of the Commonwealth of Massachusetts, and having its principal offices at 125 Summer Street, Boston, Massachusetts, 02110, is entitled to the ownership of these inventions and all applications describing these inventions by virtue of the employment and/or by contractual agreement of the inventors, and thus desires to acquire the entire right, title and interest in and to said inventions, improvements and applications and in and to the Applications, to the extent not already done so.

NOW, THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency whereof is hereby acknowledged, we, **ADEL MOUSSA** and **JEAN-PIERRE SOMMADOSSI** by these presents do sell, assign, and transfer to **ATEA PHARMACEUTICALS, INC.**, to the extent not already done so, the full, exclusive, and entire right, title, and interest in and to said Applications, and in and to all inventions and improvements disclosed and described in said Applications,

as well as all know-how derived during the development of, and directed to, the inventions and improvements disclosed and described in said Applications.


For the same consideration, we, by these presents, do sell, assign, and transfer to ATEA PHARMACEUTICALS, INC. the full, exclusive, and entire right, title, and interest in and to any U.S. nonprovisional or foreign application or any other applications that correspond to or claim priority to said Applications, in whole or in part, and to any Letters Patent and similar protective rights granted on said U.S. nonprovisional or foreign applications, and in and to the right to claim any applicable priority rights arising from or required for said U.S. nonprovisional or foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations, including to all divisions, continuations, continuations-in-part, or renewals thereof, all Letters Patent which may be granted therefrom, all reexaminations, and all reissues or extensions of such patents; said U.S. nonprovisional or foreign applications to be filed and issued in the name of ATEA PHARMACEUTICALS, INC. or its designee insofar as permitted by applicable law;

AND, for the consideration aforesaid, we do hereby agree that we and our executor(s) and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said Assignee, its successors and representatives all facts known to us relating to said improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said Assignee, its successors or assigns the entire right, title and interest in and to the said improvements, inventions, applications, Letters Patent, rights, titles, benefits, privileges and advantages hereby assigned and conveyed, or intended so to be.

AND, furthermore we covenant and agree with said Assignee, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by us and that full right to convey the same as herein expressed is possessed by us.


The Assignor agrees that this general assignment is effective from the 31st Day of January 2018.

For ATEA PHARMACEUTICALS, INC.



Andrea Corcoran
Executive Vice President

Date: 19 July 2019




ADEL MOUSSA


COMMONWEALTH OF MASSACHUSETTS

Before me, a Notary Public in and for the Commonwealth of Massachusetts, on this 19th day of July, 2019, personally appeared **ADEL MOUSSA**, who, being duly sworn, signed and acknowledged the foregoing Assignment as his free act and deed.





NOTARY PUBLIC


CYNTHIA B. GAGNE
Notary Public
COMMONWEALTH OF MASSACHUSETTS
My Commission Expires
September 8, 2024

My Commission Expires: _____


Date: 19 July 2019




JEAN-PIERRE SOMMADOSSI

COMMONWEALTH OF MASSACHUSETTS

Before me, a Notary Public in and for the Commonwealth of Massachusetts, on this 19th day of July 2019, personally appeared **JEAN-PIERRE SOMMADOSSI**, who, being duly sworn, signed and acknowledged the foregoing Assignment as his free act and deed.





NOTARY PUBLIC

My Commission Expires: _____

